Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIRPE65: AAV-RPE65 for RPE65-associated LCA
NCT02781480Phase 2Completed
- Sponsor
- MeiraGTx
- Start
- Apr 2016
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 2, open-label trial of cevaretigene ritoparvovec in Leber congenital amaurosis (LCA) (3 arms), sponsored by MeiraGTx. Primary endpoint: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event at 6 months. Started Apr 2016; status: completed.
02
Drugs
cevaretigene ritoparvovec
03
Conditions
Leber congenital amaurosis (LCA)
Beyond the preview
Go deeper on NCT02781480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781480.